Johnson & Johnson (JNJ)

Latest stories mapped to JNJ

Everything Newsig has mapped to JNJ, newest first — no importance filter. Topic pages list critical and high-importance stories only.

• 2026-10-16 US FDA sets up board to oversee drug exclusivity determinations
• 2026-10-16 Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more
• 2026-10-16 Lilly, Pfizer, J&J among winners of EU drug recommendations this month
• 2026-10-15 US delays small imports rule that raised alarm over prescription drug costs
• 2026-10-15 Congo Ebola outbreak spreads to new province bordering Central African Republic
• 2026-10-15 Bernstein raises Johnson & Johnson stock price target on solid Q3
• 2026-10-13 Johnson & Johnson raises 2026 sales outlook to 6.7%-7.1% while projecting $100.7B midpoint revenue
• 2026-10-13 Johnson & Johnson leaning toward spinning out hips-and-knees business - WSJ
• 2026-10-13 J&J shares down despite guidance raise as MedTech revenues disappoint
• 2026-10-13 Johnson & Johnson in charts: Innovative medicine growth offsets Stelara drag in Q3; U.S. sales rise 9.1% Y
• 2026-10-13 J&J falls premarket despite raised earnings guidance
• 2026-10-13 Johnson & Johnson declares $1.34 dividend
• 2026-10-13 Earnings Snapshot: Johnson & Johnson tops Q3 expectations, lifts full-year adjusted EPS guidance
• 2026-10-13 J&J beats earnings estimates; Middle East conflict weighs on medical device sales
• 2026-10-13 Johnson & Johnson Non-GAAP EPS of $2.59 beats by $0.06, revenue of $25.4B in-line
• 2026-10-12 J&J long-term Tremfya data demonstrates Crohn's remission through three years
• 2026-10-12 J&J’s Tremfya shows fistula remission in Crohn’s subgroups
• 2026-10-12 Johnson & Johnson Q3 earnings preview: EPS consensus, guidance, and key watch items
• 2026-10-12 Johnson & Johnson earnings on deck: What to expect
• 2026-10-12 Stifel holds Johnson & Johnson stock rating at Hold, $260 target